Highlighted research

Longevity of immunity against SARS-CoV-2

Published: May 11, 2020

Updated: October 13, 2023

Currently, the longevity of immunity against SARS-CoV-2 is one of the most burning questions and we will have to be patient until sufficient evidence will have been collected. Nevertheless, will ELISpot become a key tool to test for this? Maybe! Why? It has already been widely used to answer similar research questions thanks to its exceptional sensitivity to detect antigen-specific T-cell responses.

For example, previous publications using human IFN-γ ELISpot show the presence of specific T-cell responses up to 11 years after the first SARS-CoV outbreak in 2002 (Li et al., J Immunol. 2008; Ng et al., Vaccine, 2016). Time and research efforts will tell whether we will see similar immunity towards SARS-CoV-2.

Mabtech product used

Explore similar topics

Highlighted research ELISpotHumanIFN-γBasic immunologySARS-CoV-2Publication